THERAPY DOSSIER · th-d03afca21055

2-Methylthio-adenosine-5'-diphosphate (2-MesADP)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: 2-MeSADP
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32474563 ↗2020Reported benefit

A Selective P2Y Purinergic Receptor Agonist 2-MesADP Enhances Locomotor Recovery after Acute Spinal Cord Injury.

MouseSpinal cord injuryCompressionGiven after T9 crush injury, with assessment up to 6 weeks

Model: T9 crush spinal cord injury (acute)

2-MesADP improved limb motor function by 6 weeks after injury with neuronal regeneration and axon remyelination at 2 and 6 weeks, and altered expression of apoptosis, regeneration and myelination genes (Nefh, NeuroD6, Dcx, Mag, Mog, Cnp), with Wnt signalling identified as the most affected pathway.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…